1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Drugs In Development, 2022, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2 and 2 respectively.
Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Nephrotic Syndrome - Overview
- Nephrotic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Nephrotic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nephrotic Syndrome - Companies Involved in Therapeutics Development
- Adare Pharma Solutions
- APIE Therapeutics Inc
- Asahi Kasei Pharma Corp
- ChemoCentryx Inc
- NephKey Therapeutics Inc
- Ninevah Therapeutics SL
- Pharmapraxis
- SynAct Pharma AB
- Nephrotic Syndrome - Drug Profiles
- AP-1189 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APT-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APT-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ilacirnon sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mizoribine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NTX-014 - Drug Profile
- Product Description
- Mechanism Of Action
- pioglitazone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- prednisone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rituximab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- Nephrotic Syndrome - Dormant Projects
- Nephrotic Syndrome - Product Development Milestones
- Featured News & Press Releases
- Nov 23, 2021: SynAct Pharma reports positive PK data on AP1189 tablets
- Nov 11, 2021: SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
- Aug 25, 2021: SynAct strengthens IP portfolio - Grant of key European patent covering AP1189
- Jun 29, 2020: SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
- Jun 02, 2020: SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
- Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
- Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Nephrotic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Nephrotic Syndrome - Pipeline by Adare Pharma Solutions, 2022
- Nephrotic Syndrome - Pipeline by APIE Therapeutics Inc, 2022
- Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, 2022
- Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, 2022
- Nephrotic Syndrome - Pipeline by NephKey Therapeutics Inc, 2022
- Nephrotic Syndrome - Pipeline by Ninevah Therapeutics SL, 2022
- Nephrotic Syndrome - Pipeline by Pharmapraxis, 2022
- Nephrotic Syndrome - Pipeline by SynAct Pharma AB, 2022
- Nephrotic Syndrome - Dormant Projects, 2022
- Number of Products under Development for Nephrotic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adare Pharma Solutions
- APIE Therapeutics Inc
- Asahi Kasei Pharma Corp
- ChemoCentryx Inc
- NephKey Therapeutics Inc
- Ninevah Therapeutics SL
- Pharmapraxis
- SynAct Pharma AB
